1349. Lesson Learned from Investigators of Clinical Trials to Identify Therapeutics for COVID-19: Qualitative Study

Abstract Background Implementation of high-quality clinical trials especially early in the pandemic caused burden on investigators given lack infrastructure, networks and systematic supports. To prepare for future pandemic, we investigated facilitator obstacles that enable to operate COIVD-19 Japan. Methods We conducted individual semistructured qualitative interviews assess process how COVID-19 were planned implemented at stage pandemic. Clinical primarily selected through purposive sampling ensure participants involved well covered. Additional identified using snowball sampling. Interviews analyzed descriptive method. Results Through interviews, identify factors can impact conduct infectious diseases field during health emergency Japan (Figure). First, there are rolling out this theme was further divided into two subthemes: system(such as regulatory frameworks support trials, trial networks/platform, understanding attitude public trial); level (such limited resource non-academic hospitals implement trained experienced researchers coordinators with regards trials). Secondary, a few facilitate exist. Not only governmental organizational commitment but also presence physicians other healthcare professional interested conducting key trials. Facilitators therapeutics Conclusion In study, who recognized both facilitators. System likely led level. Our finding emphasizes importance care policies respond such insight from front line encourage systemwide efforts develop transparent Disclosures All Authors: No reported disclosures.